Abstract
Testosterone undecanoate is a hormone agent with long-acting potential and is used for testosterone replacement therapy for hypogonadism. This study was designed to investigate application of testosterone undecanoate in maintaining high androgen levels for inducing benign prostatic hyperplasia more conveniently than that for testosterone propionate. We conducted two-part studies to determine the optimal dosage and dosing cycle for efficient and stable induction of benign prostatic hyperplasia using testosterone undecanoate. In the injection dosage substudy, single testosterone undecanoate dose (125, 250, 500, 750, or 1000 mg/kg body weight) was administered, and the optimal concentration was determined for 8weeks by measuring changes in testosterone, dihydrotestosterone, and 5-alpha reductase levels. And then, testosterone undecanoate was administered at the optimal dose at intervals of 1, 2, 3, or 4 weeks for 12weeks to induce benign prostatic hyperplasia. The injection dosage substudy showed dose-dependently higher and more stable levels of testosterone in groups administrated testosterone undecanoate than in groups administered testosterone propionate. In the injection cycle substudy, testosterone undecanoate-administered group stably maintained high levels of testosterone, dihydrotestosterone, and 5-alpha reductase compared with testosterone propionate-administered group for the same injection cycle; moreover, the prostate measurements, an important sign of benign prostatic hyperplasia, were significantly increased. Based on these two substudies, we determined the optimal conditions for inducing benign prostatic hyperplasia stably and more conveniently than that for testosterone propionate. This study suggests an extended application of testosterone undecanoate for inducing benign prostatic hyperplasia that can improve research reliability considering the half-life of testosterone as well as injection dosage and concentration.
Funder
National Research Foundation of Korea
Publisher
Public Library of Science (PLoS)
Reference36 articles.
1. Maintenance of muscle mass in adult male mice is independent of testosterone;A Davidyan;PLoS One,2021
2. WHO Special Programme of Research, Development and Research Training in Human,Reproduction and Workshop Conference on Androgen Therapy: Biologic and Clinical Consequences (1990: Marco Island, Florida,U.S.A.). Guidelines for the use of androgens in men.
3. Endocrine History: The history of discovery, synthesis and development of testosterone for clinical use;E Nieschlag;Eur J Endocrinol,2019
4. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies;HM Behre;Eur J Endocrinol,1999
5. Development of methods of male contraception: impact of the World Health Organization Task Force;GMH Waites;Fertil Steril,2003
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献